Corticosteroids, including EMFLAZA, readily cross the placenta. Adverse developmental outcomes, including orofacial clefts (cleft lip, with or without cleft palate ) and intrauterine growth restriction , and decreased birth weight, have been reported with maternal use of corticosteroids, including EMFLAZA, during pregnancy. Some epidemiologic studies report an increased risk of orofacial clefts from about 1 per 1000 infants to 3 to 5 per 1000 infants; however, a risk for orofacial clefts has not been observed in all studies. Intrauterine growth restriction and decreased birth weight appear to be dose-related; however, the underlying maternal condition may also contribute to these risks (see Data ). The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the . general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Corticosteroid medications mimic the effects of the hormones that the adrenal glands on top of the kidneys produce, explains Mayo Clinic. They help suppress inflammation and the immune system, making them useful for treating conditions related to swelling and autoimmune disorders. Oral corticosteroid medications are often prescribed to treat rheumatoid arthritis and lupus, while inhaled preparations of these drugs may be prescribed for asthma. Topical creams containing corticosteroids may be used to heal skin conditions, and injections of these drugs are useful to reducing the pain and inflammation of tendinitis.